AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31300248 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR-negative canals (S3)
Number of subjects: 52
Study 31300248 — intervention group
Group type: EXPERIMENTAL
Intervention: S3-positive canals with <3.12 × 10^3 bacterial cell counts
Number of subjects: 52
Study 31300248 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the apical level of the root canal filling
Number of subjects: 52
Study 28681387 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Chewing Training (FuCT)
Number of subjects: 32
Study 28681387 — intervention group
Group type: COMPARATOR
Intervention: Control group (classical oral motor exercises)
Number of subjects: 32
Study 26373676 — intervention group
Group type: EXPERIMENTAL
Intervention: MYC-IG translocation patients treated with rituximab-anthracycline-based chemotherapy
Number of subjects: 774
Study 26373676 — intervention group
Group type: EXPERIMENTAL
Intervention: MYC-IG translocation patients
Number of subjects: 774
Study 26373676 — intervention group
Group type: COMPARATOR
Intervention: MYC-non-IG translocation patients
Number of subjects: 774
Study 24364373 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management intervention
Number of subjects: 250
Study 24364373 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 250
Study 24364373 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient characteristics
Number of subjects: 250
Study 22463488 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored training of household heads about the proper use of LLITN and community network system.
Number of subjects: 21673
Study 22463488 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training).
Number of subjects: 21673
Study 19631051 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (imagination condition)
Number of subjects: 60
Study 19631051 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (virtual reality condition)
Number of subjects: 60
Study 19631051 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital-based care (control)
Number of subjects: 60
Study 17549864 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral surgery
Number of subjects: 64
Study 17549864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral simultaneous surgery
Number of subjects: 64
Study 17549864 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study 15226754 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (15 mg iron and multivitamins)
Number of subjects: 49
Study 15226754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multivitamins alone)
Number of subjects: 49
Study 11445102 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg once daily for 28 days
Number of subjects: 1010
Study 11445102 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1010
Study 9543270 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation
Number of subjects: 60
Study 9543270 — intervention group
Group type: COMPARATOR
Intervention: Standard community care
Number of subjects: 60
Study 7993835 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide and cisplatin (EP)
Number of subjects: 143
Study 7993835 — intervention group
Group type: COMPARATOR
Intervention: Etoposide and carboplatin (EC)
Number of subjects: 143
Study 2465265 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine pranobex 3 g a day for four weeks
Number of subjects: 55
Study 2465265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 2465265 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine pranobex
Number of subjects: 55
Study 31539674 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (with or without virtual reality)
Number of subjects: 162
Study 31539674 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 162
Study 31539674 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 162
Study 30457965 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback balance training using inertial sensors
Number of subjects: 15
Study 30457965 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance training
Number of subjects: 15
Study 28864749 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuzhi tablet co-administration with tacrolimus
Number of subjects: 44
Study 28864749 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 genotype plus Wuzhi tablet co-administration guided dosing
Number of subjects: 44
Study 28864749 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of tacrolimus (control group)
Number of subjects: 44
Study 23114199 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver at a load of 40 mm Hg for 10 seconds
Number of subjects: 30
Study 16322487 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dextroamphetamine (AMPH) with physiotherapy
Number of subjects: 71
Study 16322487 — intervention group
Group type: COMPARATOR
Intervention: Placebo with physiotherapy
Number of subjects: 71
Study 16322487 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dextroamphetamine (AMPH) with physiotherapy in moderate hemiparesis subgroup
Number of subjects: 71
Study 12583865 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 12
Study 12583865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 12
Study 12583865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10539775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of L-[1-(13)C]oxoproline and L-[3, 3-(2)H]cysteine
Number of subjects: 5
Study 10539775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of L-[(15)N]oxoproline and L-[3,3-(2)H]cysteine
Number of subjects: 5
Study 8758790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of DDP (100mg/m2)
Number of subjects: 16
Study 8758790 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of DDP (100mg/m2)
Number of subjects: 16
Study 1913123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 60
Study 1913123 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (Sk)
Number of subjects: 60
Study 1913123 — intervention group
Group type: COMPARATOR
Intervention: Intravenous recombinant tissue plasminogen activator (IV rt-PA)
Number of subjects: 60
Study 6749773 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.13 mg
Number of subjects: 7
Study 6749773 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.26 mg
Number of subjects: 7
Study 6749773 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of atropine (exact dosage not specified)
Number of subjects: 7
Study 6749773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31898516 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children - for Teachers (ICC-T) intervention
Number of subjects: 1200
Study 31898516 — intervention group
Group type: COMPARATOR
Intervention: Monitoring group (no intervention)
Number of subjects: 1200
Study 31440032 — intervention group
Group type: EXPERIMENTAL
Intervention: IDP‐73152 mesylate 40-320 mg
Number of subjects: 56
Study 31440032 — intervention group
Group type: EXPERIMENTAL
Intervention: IDP‐73152 mesylate 640 mg (fed state)
Number of subjects: 56
Study 31440032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 26320145 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance-based exercise intervention for 3 months
Number of subjects: 189
Study 26320145 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 189
Study 26053170 — intervention group
Group type: EXPERIMENTAL
Intervention: SPD left‐side down (SPD‐L)
Number of subjects: 20
Study 26053170 — intervention group
Group type: EXPERIMENTAL
Intervention: SPD right‐side down (SPD‐R)
Number of subjects: 20
Study 26053170 — intervention group
Group type: COMPARATOR
Intervention: Standard wedge (W)
Number of subjects: 20
Study 26053170 — intervention group
Group type: COMPARATOR
Intervention: Flat (F)
Number of subjects: 20
Study 23277897 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose influenza vaccine (60 mcg/strain)
Number of subjects: 195
Study 23277897 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose influenza vaccine (15 mcg/strain)
Number of subjects: 195
Study 21593294 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of 5 to <10% (mean 7.25±2.1 kg)
Number of subjects: 5145
Study 19879995 — intervention group
Group type: EXPERIMENTAL
Intervention: LEISH-F1+MPL-SE vaccine (10 microg recombinant Leishmania polyprotein LEISH-F1 antigen + 25 microg MPL-SE adjuvant)
Number of subjects: 80
Study 19879995 — intervention group
Group type: EXPERIMENTAL
Intervention: LEISH-F1+MPL-SE vaccine
Number of subjects: 80
Study 19879995 — intervention group
Group type: COMPARATOR
Intervention: 10 microg LEISH-F1 protein alone
Number of subjects: 80
Study 19879995 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 80
Study 16930788 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional digital blocks
Number of subjects: 0
Study 16930788 — intervention group
Group type: COMPARATOR
Intervention: Single subcutaneous palmar injection blocks
Number of subjects: 0
Study 16930788 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar techniques (including single subcutaneous palmar block and transthecal block)
Number of subjects: 0
Study 15521842 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (2-month course)
Number of subjects: 15
Study 15521842 — intervention group
Group type: COMPARATOR
Intervention: Control (inactive Crohn's disease)
Number of subjects: 15
Study 11744511 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet History Questionnaire (DHQ)
Number of subjects: 1301
Study 11744511 — intervention group
Group type: EXPERIMENTAL
Intervention: Block FFQ
Number of subjects: 1301
Study 11744511 — intervention group
Group type: EXPERIMENTAL
Intervention: Willett FFQ
Number of subjects: 1301
Study 11744511 — intervention group
Group type: EXPERIMENTAL
Intervention: DHQ
Number of subjects: 1301
Study 11744511 — intervention group
Group type: EXPERIMENTAL
Intervention: All three FFQs (DHQ, Block, Willett)
Number of subjects: 1301
Study 9331018 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 0
Study 9331018 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 0
Study 9331018 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (combined treatment)
Number of subjects: 0
Study 9331018 — intervention group
Group type: COMPARATOR
Intervention: Candesartan cilexetil
Number of subjects: 0
Study 8281056 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise training
Number of subjects: 224
Study 8281056 — intervention group
Group type: COMPARATOR
Intervention: Light exercise
Number of subjects: 224
Study 3120484 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural nicomorphine post-operatively
Number of subjects: 129
Study 3120484 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular nicomorphine post-operatively
Number of subjects: 129
Study 30206090 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine hydrochloride (300 mg/day) administered orally three times a day for 4 weeks (period 1)
Number of subjects: 0
Study 30206090 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally three times a day for 4 weeks (period 1)
Number of subjects: 0
Study 26852276 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 465
Study 26852276 — intervention group
Group type: COMPARATOR
Intervention: No Radiotherapy (no-RT)
Number of subjects: 465
Study 24682569 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring of ventricular rate (VR) during atrial fibrillation (AF)
Number of subjects: 1404
Study 24347765 — intervention group
Group type: EXPERIMENTAL
Intervention: melatonin (6 mg)
Number of subjects: 130
Study 24347765 — intervention group
Group type: EXPERIMENTAL
Intervention: gabapentin (600 mg)
Number of subjects: 130
Study 24347765 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 130
Study 20887535 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact with fathers for 30 minutes after initial 5 minutes with mothers
Number of subjects: 37
Study 20887535 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact with mothers for 30 minutes after initial 5 minutes with mothers
Number of subjects: 37
Study 20887535 — intervention group
Group type: COMPARATOR
Intervention: Control group (fathers and mothers without skin-to-skin contact)
Number of subjects: 37
Study 18237297 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized device (Wand, Milestone Scientific)
Number of subjects: 41
Study 18237297 — intervention group
Group type: COMPARATOR
Intervention: Traditional plastic syringe
Number of subjects: 41
Study 18237297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-injection anxiety levels
Number of subjects: 41
Study 16623830 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit mirror-tracing learning task
Number of subjects: 48
Study 16623830 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit word-pair association learning task
Number of subjects: 48
Study 16623830 — intervention group
Group type: COMPARATOR
Intervention: Control task (corresponding to learning tasks)
Number of subjects: 48
Study 14725135 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy
Number of subjects: 36
Study 14725135 — intervention group
Group type: COMPARATOR
Intervention: Reassurance by nurse practitioner
Number of subjects: 36
Study 11106143 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg in a controlled-release formulation)
Number of subjects: 14
Study 11106143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9064946 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (maximal dose: 9 micrograms/kg/min; n = 10)
Number of subjects: 20
Study 9064946 — intervention group
Group type: COMPARATOR
Intervention: Milrinone (0.5 microgram/kg/min; n = 10)
Number of subjects: 20
Study 1370510 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT) with alum-precipitated aqueous ragweed extracts
Number of subjects: 27
Study 1370510 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27
Study 6383654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (average dose 845,000 U iv, administered at 2.8 ± 1.0 hr after onset of pain)
Number of subjects: 50
Study 6383654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (average dose 212,000 U ic, administered at 4.3 ± 1.4 hr after onset of pain)
Number of subjects: 50
Study 6383654 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (not specified dosage or timing)
Number of subjects: 50
Study 31521917 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 92
Study 31521917 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinative training
Number of subjects: 92
Study 31521917 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 92
Study 30261892 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble keratin (KER) 0.8 g/kg bodyweight/day
Number of subjects: 15
Study 30261892 — intervention group
Group type: COMPARATOR
Intervention: Casein protein (CAS)
Number of subjects: 15
Study 30261892 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble keratin (KER)
Number of subjects: 15
Study 26817502 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg Zn/d)
Number of subjects: 31
Study 26817502 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 mg Zn/d)
Number of subjects: 31
Study 24472253 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of preschool-based social communication treatment in addition to standard preschool program
Number of subjects: 61
Study 24472253 — intervention group
Group type: COMPARATOR
Intervention: Standard preschool program only
Number of subjects: 61
Study 23257132 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianggu Capsule and two disease-modifying antirheumatic drugs
Number of subjects: 82
Study 23257132 — intervention group
Group type: COMPARATOR
Intervention: Two common-used antirheumatic drugs
Number of subjects: 82
Study 20698724 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 g tranexamic acid
Number of subjects: 48
Study 20698724 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.9 g tranexamic acid
Number of subjects: 48
Study 20698724 — intervention group
Group type: COMPARATOR
Intervention: 0.4 g moxifloxacin (positive control)
Number of subjects: 48
Study 20698724 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 48
Study 17686152 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (200 + 100 + 100 microg/kg)
Number of subjects: 30
Study 17686152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15458612 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract (HE) 900 mg/d
Number of subjects: 135
Study 15458612 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d
Number of subjects: 135
Study 15458612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 12467852 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound waveform estimation
Number of subjects: 204
Study 10432323 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 480
Study 7594327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg and clarithromycin 400 mg (group 1, n = 22)
Number of subjects: 58
Study 7594327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg and clarithromycin 800 mg (group 2, n = 12)
Number of subjects: 58
Study 7594327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg and clarithromycin 800 mg (group 3, n = 29)
Number of subjects: 58
Study 7594327 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg (n = 23)
Number of subjects: 58
Study 7594327 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 60 mg (n = 13)
Number of subjects: 58
Study 7594327 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg (n = 15)
Number of subjects: 58
Study 2110788 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 30
Study 2110788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 160348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 200 mg twice daily
Number of subjects: 46
Study 160348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 100 mg twice daily
Number of subjects: 46
Study 160348 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg thrice daily
Number of subjects: 46
Study 160348 — intervention group
Group type: COMPARATOR
Intervention: Soluble aspirin 600 mg thrice daily
Number of subjects: 46
Study 30512122 — intervention group
Group type: EXPERIMENTAL
Intervention: Fab antivenom (FabAV)
Number of subjects: 74
Study 30512122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 27785095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nattokinase (100 mg/d)
Number of subjects: 79
Study 27785095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 23881520 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care Program (SCP)
Number of subjects: 136
Study 23881520 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 136
Study 24337425 — intervention group
Group type: EXPERIMENTAL
Intervention: New back school intervention
Number of subjects: 88
Study 20452366 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Attention to Response Task (SART)
Number of subjects: 0
Study 20452366 — intervention group
Group type: EXPERIMENTAL
Intervention: SART
Number of subjects: 0
Study 18549711 — intervention group
Group type: EXPERIMENTAL
Intervention: Subglottic secretion drainage (SSD)
Number of subjects: 61
Study 18549711 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 16094519 — intervention group
Group type: EXPERIMENTAL
Intervention: Equimolar mixture of nitrous oxide/oxygen (EMNO)
Number of subjects: 83
Study 16094519 — intervention group
Group type: COMPARATOR
Intervention: Placebo mixture (50% oxygen and 50% nitrogen)
Number of subjects: 83
Study 11167594 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy (including chemotherapy)
Number of subjects: 86
Study 11167594 — intervention group
Group type: EXPERIMENTAL
Intervention: More than one course of chemotherapy
Number of subjects: 86
Study 11167594 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant systemic therapy
Number of subjects: 86
Study 9728898 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (1.5 gm/day for 2 days)
Number of subjects: 12
Study 9728898 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day for 2 days)
Number of subjects: 12
Study 9728898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8050255 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific letters
Number of subjects: 288
Study 8050255 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminders
Number of subjects: 288
Study 8050255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 288
Study 3056820 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal-systemic shunt
Number of subjects: 81
Study 3056820 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt
Number of subjects: 81
Study 1424416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 mg
Number of subjects: 12
Study 1424416 — intervention group
Group type: COMPARATOR
Intervention: Placebo-alcohol
Number of subjects: 12
Study 277253 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole
Number of subjects: 0
Study 277253 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hyperbaric oxygen and misonidazole
Number of subjects: 0